|80. In adults receiving treatment with TNFi, we conditionally recommend against co-treatment with low-dose methotrexate.|Low|77|
|81. We conditionally recommend the regular-interval use and monitoring of a validated AS disease activity measure.†|Very low|56|
|82. We conditionally recommend regular-interval use and monitoring of the CRP concentrations or ESR over usual care without regular CRP or ESR monitoring.†|Very low|57|